Poliovirus

Who tracked UK COVID infections the best at the height of the pandemic? A new study provides the answer

Retrieved on: 
Tuesday, October 17, 2023

We wanted to know which of these methods was the most reliable during the first two years of the pandemic.

Key Points: 
  • We wanted to know which of these methods was the most reliable during the first two years of the pandemic.
  • The gold standard surveillance was the Office for National Statistics (ONS) COVID survey.
  • This data tracked the ONS estimates very closely, though the reported numbers were usually only about 45% of the ONS data.
  • The Zoe app also tracked the ONS survey estimates closely and was a good estimate of whether infections were rising or falling.
  • For COVID, the question was can wastewater testing indicate how much infection is present in the population?
  • In our analysis, we found that counts in wastewater were moderately correlated with the prevalence of COVID in the population.

Useful additional insights

    • Even so, the other approaches provided useful additional insights.
    • NHS 111 call and website data provided useful information early in the pandemic, before other surveillance methods were established.
    • Although wastewater surveillance did little to increase our understanding of the course of the pandemic in England, this surveillance method may be useful in countries that don’t have easy access to human testing.

WHO Launching Polio Eradication Campaign in Pakistan Using PharmaJet Precision Delivery System

Retrieved on: 
Tuesday, May 23, 2023

PharmaJet ®, a company engineering precision delivery systems that overcome the challenges of vaccine delivery, today announced their support for the World Health Organization’s (WHO) polio eradication campaigns in Pakistan starting in May 2023.

Key Points: 
  • PharmaJet ®, a company engineering precision delivery systems that overcome the challenges of vaccine delivery, today announced their support for the World Health Organization’s (WHO) polio eradication campaigns in Pakistan starting in May 2023.
  • The PharmaJet Tropis Precision Delivery System™ (PDS) was selected based on its proven cost savings, ease of training, and improved immunization coverage benefits.
  • The WHO previously introduced needle-free intradermal delivery of inactivated polio vaccine (ID-IPV) in Pakistan and Somalia using the PharmaJet Tropis ID PDS for the immunization of millions of children.
  • “Very much like COVID, as long as we have polio transmission anywhere, potentially everywhere is at risk.

Government of Canada supports wastewater monitoring for COVID-19 in Atlantic Canada

Retrieved on: 
Tuesday, January 17, 2023

Wastewater data is an important early warning sign for public health action and decisions for the benefit of communities in Atlantic Canada.

Key Points: 
  • Wastewater data is an important early warning sign for public health action and decisions for the benefit of communities in Atlantic Canada.
  • Wastewater monitoring has been essential in COVID-19 monitoring and is one of the key tools guiding the future of public health surveillance.
  • The Government of Canada has committed $28.1 million since May 2020 to establish, expand and enhance the pan-Canadian wastewater surveillance program.
  • "Wastewater monitoring is the future of public health surveillance for infectious diseases in Canada.

On World Polio Day 2022, PharmaJet Announces $1.5 million Grant From USAID to Evaluate Use of Needle-Free Delivery in Routine Polio Immunization

Retrieved on: 
Monday, October 24, 2022

The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).

Key Points: 
  • The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
  • A preferred approach by healthcare workers and patients1 is needle-free ID delivery using Tropis, which was developed with support from the World Health Organization (WHO) and Bill & Melinda Gates Foundation.
  • On this World Polio Day 2022, we restate our commitment to the Global Polio Eradication Initiative and we are pleased to receive this grant from USAID Development Innovation Ventures.
  • Their advocacy efforts have played a role in decisions by governments to contribute more than $10 billion to the effort.

Bloomberg Philanthropies Commits Additional $50 Million to Eradicate Polio

Retrieved on: 
Tuesday, October 18, 2022

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Bloomberg Philanthropies today announced an additional $50 million commitment to the Global Polio Eradication Initiative (GPEI) reinforcing its dedication to GPEI's mission to complete the global eradication of polio. This renewal of support comes at a time when polio is rebounding, following a fall in vaccination rates during the COVID-19 pandemic and a heightened risk of a polio resurgence, and brings Bloomberg Philanthropies total commitment to GPEI to $225 million since 2013.

Key Points: 
  • NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Bloomberg Philanthropies today announced an additional $50 million commitment to the Global Polio Eradication Initiative (GPEI) reinforcing its dedication to GPEI's mission to complete the global eradication of polio.
  • "Until we eradicate polio from the world, it poses a risk to people everywhere," said Michael R. Bloomberg, founder of Bloomberg Philanthropies and WHO Global Ambassador for Noncommunicable Diseases and Injuries.
  • "Since 2013, Bloomberg Philanthropies has been glad to support the critically important work of the Global Polio Eradication Initiative and now, as polio outbreaks threaten the critical progress we've made, we're recommitting to the urgent fight to end polio for good."
  • "Eradicating polio will require the full support of the global health community," said Dr. Kelly Henning, who leads Public Health programs at Bloomberg Philanthropies.

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors

Retrieved on: 
Sunday, April 3, 2022

TAB009/JS009 is a recombinant humanized IgG4 monoclonal antibody against human CD112R developed independently by Junshi Biosciences, for the treatment of advanced malignant tumors.

Key Points: 
  • TAB009/JS009 is a recombinant humanized IgG4 monoclonal antibody against human CD112R developed independently by Junshi Biosciences, for the treatment of advanced malignant tumors.
  • The investigational new drug application for TAB006/JS006 has already been approved by both Chinas National Medical Products Administration (NMPA) and the U.S. FDA.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Physicians for Informed Consent Updates Its Information Statement About Vaccines and Immunocompromised Schoolchildren, Includes Data on COVID-19 Vaccines

Retrieved on: 
Monday, March 28, 2022

NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"

Key Points: 
  • NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"
  • Thus, informed consent and informed refusal in vaccination are both logical and moral, and there is no justification to mandate schoolchildren receive COVID-19 vaccines, or any other vaccines."
  • PIC delivers data on infectious diseases and vaccines, and unites doctors, scientists, healthcare professionals, attorneys, and families who support voluntary vaccination.
  • In addition, the PIC Coalition for Informed Consent consists of over 300 U.S. and international organizations.

Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats

Retrieved on: 
Thursday, February 10, 2022

Altesa BioSciences, Inc., an independently operated, for-profit biotechnology company today launched operations to develop and commercialize novel anti-viral drugs against common respiratory viruses like rhinovirus and parainfluenza, and vector-born global viral threats like Dengue fever, Yellow Fever, Zika, and Powassan.

Key Points: 
  • Altesa BioSciences, Inc., an independently operated, for-profit biotechnology company today launched operations to develop and commercialize novel anti-viral drugs against common respiratory viruses like rhinovirus and parainfluenza, and vector-born global viral threats like Dengue fever, Yellow Fever, Zika, and Powassan.
  • Altesas DRIVE/Emory collaborators are responsible for some of the most acclaimed life-saving and commercially-successful drugs worldwide, including Emtriva and Molnupiravir.
  • Altesa thereafter closed a $4 million seed funding round led by Pitango Venture Capital and joined by the GRA Venture Fund.
  • Altesa BioSciences, Inc., is a biopharmaceutical company based in Atlanta, focused on developing antivirals to addresses diseases of global importance.

GLIDE: Vaccination Incentives and Next Generation Sequencing – Two Pakistani Doctors Employ Innovative Techniques to Eradicate Polio

Retrieved on: 
Monday, December 13, 2021

Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.

Key Points: 
  • Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.
  • It is possible his methods could also be used to control other infectious diseases in the region, including COVID-19.
  • With GLIDEs support, my project will focus on improving polio vaccination coverage in these high-risk areas which will hopefully contribute to eradicating this disease from the world.
  • Dr Das and Dr Salman beat 220 applicants across 44 countries to become the first Pakistani winners of the Falcon Awards.